To translate these findings into a therapeutic strategy, we developed a recombinant adeno-associated virus serotype 2 (AAV2) vector expressing ABTB2 under the control of a cyclooxygenase-2 (COX2) promoter, enabling tumor-selective expression. This evidence concerns the gene PTGS2 and neoplasm.